Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Ann Intern Med 2020 Jun 16;172(12):819-821

Date

04/01/2020

Pubmed ID

32227189

Pubmed Central ID

PMC7138335

DOI

10.7326/M20-1223

Scopus ID

2-s2.0-85083710801 (requires institutional sign-in at Scopus site)   163 Citations

Abstract

Hydroxychloroquine, an essential treatment for many patients with rheumatologic conditions, has recently garnered widespread attention as a potential treatment for COVID-19 infection. The authors appraise the study generating this interest and highlight the potential consequences of rapid dissemination of overinterpreted data, particularly for people with conditions for which hydroxychloroquine has demonstrated benefits in preventing organ damage and life-threatening disease flares.

Author List

Kim AHJ, Sparks JA, Liew JW, Putman MS, Berenbaum F, Duarte-García A, Graef ER, Korsten P, Sattui SE, Sirotich E, Ugarte-Gil MF, Webb K, Grainger R, COVID-19 Global Rheumatology Alliance

Author

Michael Putman MD Assistant Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Antiviral Agents
Azithromycin
Betacoronavirus
Clinical Trials as Topic
Coronavirus Infections
Humans
Hydroxychloroquine
Information Dissemination
Mass Media
Pandemics
Pneumonia, Viral
Research Design